Henn Matthew R.
Known title: See RemarksCIK: 0001767321
Associated companies
Transaction History
| MCRB | ▼ Sell | Open Market | 81 | $369 | 8/17/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 238 | — | 8/15/2026 | View on chart |
| MCRB | ▼ Sell | Open Market | 77 | $580 | 5/18/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 238 | — | 5/15/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 239 | — | 2/15/2026 | View on chart |
| MCRB | ▼ Sell | Open Market | 89 | $754 | 2/15/2026 | View on chart |
| MCRB | ▼ Sell | Open Market | 1,257 | $22K | 11/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 140 | — | 11/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 3,998 | — | 11/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 98 | — | 11/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 73 | $1K | 8/18/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 141 | — | 8/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 97 | — | 8/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 77 | $561 | 5/16/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 98 | — | 5/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 140 | — | 5/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 3,953 | $3K | 2/18/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,813 | — | 2/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 7,813 | — | 2/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 927 | $501 | 11/18/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,812 | — | 11/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 3,984 | $3K | 10/28/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 12,622 | $0 | 10/27/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 923 | $775 | 8/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,813 | — | 8/15/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,812 | — | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 891 | $838 | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 4,170 | $5K | 2/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 11,250 | — | 2/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 3,886 | $5K | 10/30/2023 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 12,623 | $0 | 10/27/2023 | View on chart |
| MCRB | ▲ Buy | Grant | 47,619 | $150K | 7/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026
Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026. Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.